Feb 14 (Reuters) - CSL Ltd (CSL) :
- STRONG GROWTH IN PLASMA COLLECTIONS AND IN IMMUNOGLOBULINS FRANCHISE IS EXPECTED TO CONTINUE
- HY REPORTED NET PROFIT AFTER TAX ATTRIBUTABLE $1,623.2 MILLION VERSUS $1,760.3 MILLION
- HY UNDERLYING NET PROFIT AFTER TAX AT CONSTANT CURRENCY UP 10% TO US$1.957 BILLION
- INTEGRATION OF CSL VIFOR IS WELL ADVANCED AND THE DELIVERY OF THE SYNERGIES ARE ON TRACK
- DECLARES INTERIM DIVIDEND OF US$ 1.07 PER SHARE
- SEQIRUS IS EXPECTED TO DELIVER ANOTHER PROFITABLE YEAR
- HY TOTAL REVENUE $ 7,183.5 MILLION VERSUS $6,041.2 MILLION
- ANTICIPATED THAT SEQIRUS WILL MAKE A LOSS IN THE SECOND HALF OF THE YEAR
News: CSL CSL Says Strong Growth In Plasma Collections, Immunoglobulins Franchise Expected To...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$257.38 |
Change
8.990(3.62%) |
Mkt cap ! $124.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $258.31 | $251.10 | $370.9M | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $257.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $257.38 | 3331 | 1 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |